– Advertisement –
Copenhagen-based Scandinavian Biolabs (SBL) has raised a €4 million funding round led by Auréa Group, with significant contributions from Blazar Capital and strategic support from SevenVentures, part of ProSiebenSat.1 Group. successfully completed. Founded in 2020, the company specializes in non-invasive solutions for early stage hair loss, and its flagship product, Bio-Pilixin® Activation Serum, has shown promising results in clinical trials. The new capital will be used to grow SBL’s market presence in the UK, Germany and the US, alongside expanding its online offering and building partnerships with retail pharmacies.
Founded in 2020, Scandinavian Biolab has established itself as a leader in science-backed, non-invasive prevention products targeting early-stage hair loss. The company’s flagship product, Bio-Pilixin® Activation Serum, has revolutionized the market and is being clinically tested for its positive effects.
Anders Reckendorff, CEO and co-founder of Scandinavian Biolabs, said: “We have built a strong foundation with innovative products and proven that if we can deliver value and results to our customers, we can also have a strong business. Through our experience and know-how, we will continue to grow our company. We are very pleased to have new investors join us who will contribute to our efforts.”
Scandinavian Biolabs was initially launched as a direct-to-consumer (DTC) brand and quickly built a loyal customer base through its online platform. Building on this success, the brand expanded to multiple regional retail stores and various pharmacies. With over 140,000 customers supported to date and a Trustpilot score of 4.5 out of 5, Scandinavian Biolabs is committed to being the recommended solution for reliable, tested, honest hair care products that are right for you. It’s progressing rapidly.
SevenVentures (part of the Pro. SiebenSat.1 group) supports its expansion in Germany through strategic television collaborations.
A €4 million cash injection from Aurea will enable Scandinavian Biolabs to pursue its ambitious growth plans more aggressively, establishing a leadership position in the UK, Germany and the Nordic countries, as well as entering the US market. It will be. The funding will help grow the business through online offerings and expand strategic retail operations such as pharmacies.
Scandinavian Biolabs is dedicated to advancing hair care science. Bio-Pilixin® Serum has undergone clinical pilot testing, including a 5-month study that showed a reduction in hair loss was recorded in 93% of participants. The company plans additional clinical trials to further test the effectiveness of its current and new products. The effectiveness of the product is further supported by a strong and growing repeat customer base.
Aurea Fund: “Aurea is delighted to have been selected as a preferred investor in Scandinavian BioLabs, due to the experience and operational added value we bring in addition to the growth capital. We believe in the truly differentiated and effective products they have developed and we are confident that together we can grow this into a significant international brand.”
Seven Ventures: “Scandinavian Biolabs has not only developed an innovative product line, but also built a strong brand that resonates with consumers. Our collaboration leverages the power of television to convey their message. We see great potential in this partnership as we reach millions more and highlight their unique approach to hair care.”
Blazer Capital: “We have supported Scandinavian Biolabs since the beginning and their progress has been amazing. This latest investment is a natural next step for them and we are excited about the impact it will have. looking forward to it.”
Scandinavian Biolabs was born out of a very personal battle. Co-founder Niels Conradi faced the early stages of hair loss in his 20s. This is a challenge that can crush anyone’s confidence. Instead of opting for invasive treatments, Niels set out to create a better solution. In collaboration with leading experts in chemistry, dermatology and hair science, Bio-Pilixin® Activation Serum was developed. It is the result of a constant dedication to creating something tried, tested and honest.
Niels Konradi, COO and co-founder of Scandinavian Biolabs, said: It’s incredible to see how many lives our products have touched. We’re particularly excited about the potential to provide even more value to our customers. ”
In just four years, Scandinavian Biolabs has grown from a start-up to a market leader. With revenues predicted to exceed €10 million in 2024, we are one of the fastest growing brands in the industry, with loyal customers who trust the brand to deliver real results and transparent communication. We are forming a community.
Scandinavian Biolabs doesn’t play around when it comes to clinical research. The company’s flagship product, Bio-Pilixin® Activation Serum, showed a 16% increase in anagen (growth) phase and 39% decrease in telogen (shedding) phase in participants’ hair follicles compared to baseline. was shown in the test. 93% of users see a difference, and this result is highlighted by +1,300 5-star reviews.
Hair loss affects millions of people around the world, and Scandinavian Biolab is at the forefront of providing effective, non-invasive solutions. Scandinavian Biolabs’ products are designed to work with the body’s natural processes, offering a drug-free, preventive approach to people suffering from hair loss.
Scandinavian Biolabs focuses on consumer education and ambitious and creative marketing, building on its already strong pharmacy partners such as John Bell & Croydon and retailers such as Flaconi and Healthum. We will expand our retail presence.
Click to read more funding news.
– Advertisement –
